Access the full text.
Sign up today, get DeepDyve free for 14 days.
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
Sarah L. Pett Faculty of Medicine, National Centre in HIV Purpose of review Epidemiology and Clinical Research, University of New The purpose of this review is to describe the current status of immunotherapies for the South Wales, Darlinghurst, New South Wales, Australia treatment of HIV-1 infection. This review is timely, as the results of the phase III Correspondence to Dr Sarah L. Pett, MRCP, FRACP, clinical trials of recombinant interleukin-2 (rIL-2) as adjuncts to combination antiretroviral Faculty of Medicine, National Centre in HIV Epidemiology and Clinical Research, University of New therapy are about to be released. South Wales, Darlinghurst, NSW 2010, Australia Recent findings Tel: +61 2 9385 0900; fax: +61 2 9385 0910; e-mail: spett@nchecr.unsw.edu.au For many years, the use of rIL-2 in HIV-infected individuals has been explored. Although the results of the clinical endpoint studies of rIL-2 are awaited, there are now further data Current Opinion in HIV and AIDS 2009, 4:188–193 for rIL-2 as a stand-alone therapy for the treatment of HIV. Maraviroc, a recently approved anti-HIV agent, is a small molecule antagonist of human chemokine receptor- 5. The recent observation that maraviroc-treated patients achieved higher CD4 and CD8 T-cell counts compared with comparator regimens (without
Current Opinion in HIV and Aids – Wolters Kluwer Health
Published: May 1, 2009
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.